PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28143892-4	2017	Apigenin significantly attenuated the DOCA-salt-induced structural and functional damage to the kidney, which was accompanied by reduced expression of transforming growth factor-beta1 (TGF-beta1)/Smad2/3 signaling pathway and extracellular matrix proteins.	Desoxycorticosterone Acetate	38-42	transforming growth factor, beta 1	Rattus norvegicus	185-194	
21330937-8	2011	Aortic mRNA and protein levels of transforming growth factor-beta1 (TGF-beta1), plasminogen activator inhibitor 1 (PAI-1), and monocyte chemoattractant protein 1 (MCP-1) were significantly (P<0.05) higher in the untreated DOCA rats and were normalized by fasudil administration.	Desoxycorticosterone Acetate	225-229	transforming growth factor, beta 1	Rattus norvegicus	34-66	
23323219-6	2012	Moreover, the phosphorylation of PI3K, Akt, and mTOR was increased in the kidney of DOCA-salt hypertensive rats compared with the control, as was the protein expression of ED-1, COX-2, TGF-beta1, and alpha-SMA.	Desoxycorticosterone Acetate	84-88	transforming growth factor, beta 1	Rattus norvegicus	185-194	
12850397-3	2003	Renal cortical TGF-beta(1) mRNA levels were, however, higher in DOCA-salt hypertensive rats.	Desoxycorticosterone Acetate	64-68	transforming growth factor, beta 1	Rattus norvegicus	15-26	
15097242-6	2004	Two weeks after the treatment with DOCA and salt, mRNA expression of PI and PIII, TGF-beta1, PAI-1, MCP-1 and IL-6 increased significantly.	Desoxycorticosterone Acetate	35-39	transforming growth factor, beta 1	Rattus norvegicus	82-91	
18250361-3	2008	Exposure to DOCA initiated a sequence of events that initially involved reduced PTC density, followed by a delayed response that involved further reduced PTC density, development of tubulointerstitial fibrosis and hypertension, enhanced expression of transforming growth factor-beta1 and connective tissue growth factor, and impaired renal function.	Desoxycorticosterone Acetate	12-16	transforming growth factor, beta 1	Rattus norvegicus	251-283	
11208696-9	2001	TGF-beta(1) mRNA and TGF-beta(1) protein increased at 1 week in DOCA-salt rats and were lowered in ET(A) antagonist-treated rats.	Desoxycorticosterone Acetate	64-68	transforming growth factor, beta 1	Rattus norvegicus	0-11	
11208696-9	2001	TGF-beta(1) mRNA and TGF-beta(1) protein increased at 1 week in DOCA-salt rats and were lowered in ET(A) antagonist-treated rats.	Desoxycorticosterone Acetate	64-68	transforming growth factor, beta 1	Rattus norvegicus	21-32	
8039844-3	1994	Renal mRNA levels for TGF-beta 1; types I, III, and IV collagen; and fibronectin in DOCA-salt hypertensive rats were increased by severalfold (P < .01) compared with sham-operated rats.	Desoxycorticosterone Acetate	84-88	transforming growth factor, beta 1	Rattus norvegicus	22-32	
8761033-4	1996	In the case of ECs from DOCA-salt hypertensive rats, the potencies of TGF-beta 1- or thrombin-induced action was much less than that seen with sham rats, while the difference of reactivity to FK409 was not observed between ECs of DOCA-salt rats and sham rats.	Desoxycorticosterone Acetate	24-28	transforming growth factor, beta 1	Rattus norvegicus	70-80	
8761033-4	1996	In the case of ECs from DOCA-salt hypertensive rats, the potencies of TGF-beta 1- or thrombin-induced action was much less than that seen with sham rats, while the difference of reactivity to FK409 was not observed between ECs of DOCA-salt rats and sham rats.	Desoxycorticosterone Acetate	230-234	transforming growth factor, beta 1	Rattus norvegicus	70-80	
8761033-6	1996	In addition, there seems to be an abnormalities in the signaling pathway via TGF-beta 1- or thrombin-induced enhancement of ET-1 production in ECs of DOCA-salt hypertensive rats.	Desoxycorticosterone Acetate	150-154	transforming growth factor, beta 1	Rattus norvegicus	77-87	
8039844-4	1994	In the aorta of DOCA-salt hypertensive rats, TGF-beta 1 and fibronectin mRNA levels were increased, but types I, III, and IV collagen mRNAs did not increase.	Desoxycorticosterone Acetate	16-20	transforming growth factor, beta 1	Rattus norvegicus	45-55	
8039844-8	1994	However, the increase in renal mRNAs for TGF-beta 1 and extracellular matrix components in DOCA-salt hypertensive rats was significantly inhibited by treatment with TCV-116 or enalapril, which was associated with a significant decrease in urinary protein and albumin excretions and histological improvement of renal lesions.	Desoxycorticosterone Acetate	91-95	transforming growth factor, beta 1	Rattus norvegicus	41-51	
8039844-10	1994	Thus, local Ang II may contribute to renal injury of DOCA-salt hypertension by stimulating the gene expression of TGF-beta 1 and extracellular matrix components.	Desoxycorticosterone Acetate	53-57	transforming growth factor, beta 1	Rattus norvegicus	114-124